louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05616390: Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Official title: A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular Carcinoma
Sintilimab
Bevacizumab
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2022-11-15
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma


Eligibility criteria: Inclusion Criteria:

* Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology
* Age 20-79
* At least one measurable lesion defined in RECIST version 1.1
* Child Pugh grade B
* ECOG PS score 2
* The expected life is at least 90 days

Exclusion Criteria:

* Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cells
* Received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment
* Complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases
* History of pleural or pericardial adhesions within 28 days before enrollment
* HIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positive
* Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years)
* Brain or meningeal metastasis (unless asymptomatic and does not require treatment)
* Uncontrollable or serious cardiovascular disease.

Primary outcomes:
measure: Adverse Events (AEs)
timeFrame: Up to 3 years
measure: Overall survival (OS)
timeFrame: Up to 3 years
Secondary outcomes:
measure: Overall response rate (ORR)
timeFrame: Up to 1 years
measure: Disease control rate (DCR)
timeFrame: Up to 1 years
measure: Quality of Life (QoL)
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT05132790: Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
Official title: Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Breast Cancer
Keywords: breast cancer
Lead sponsor: Shengjing Hospital
Sponsor class: OTHER
Collaborators: name: Jiangsu HengRui Medicine Co., Ltd.
First posted: 2021-11-24
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, HER2-negative breast cancer


Eligibility criteria: Inclusion Criteria:

* Confirmed histologic diagnosis of invasive adenocarcinoma of the breast
* ER, PR and HER2 testing, and
* TNBC patients （ HER2-neu 0-1+ by IHC or FISH-negative by ASCO CAP guidelines）
* ER-positive and HER2-negative breast cancer
* tumor measuring ≥2 cm in maximal diameter as measured by any available standard of care imaging (mammogram, breast ultrasound, breast MRI)
* Any nodal status
* ECOG Performance Status of 0 -1
* Screening laboratory values must meet the following criteria:

  i. Absolute neutrophil count (ANC) ≥1.5 × 109/L ii. Platelets ≥100 × 109/L iii. Hemoglobin ≥ 10.0 g/dl for TNBC, ≥ 10.0 g/dl for HR+/HER2-BC iv. Serum creatinine ≤1.5 x upper limit of normal (ULN) v. AST ≤ 2.5 xULN vi. ALT ≤ 2.5 x ULN vii. Total bilirubin ≤ 2.5 xULN viii left ventricular ejection fraction ≥ 50%.

Exclusion Criteria:

* Any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy, endocrine therapy and so on
* Inflammatory breast cancer
* Pregnant and lactating women;
* distant metastasis
* patients who have participated in other clinical trials.

Primary outcomes:
measure: Pathological complete response (pCR) for TNBC group
timeFrame: Up to11 months
measure: Residual cancer burden (RCB) 0-I index for HER2-/HR+BC group
timeFrame: Up to11 months
Secondary outcomes:
measure: Pathological complete response (pCR) forHER2-/HR+BC group
timeFrame: Up to11 months
measure: Residual cancer burden (RCB) 0-I index for TNBC group
timeFrame: Up to11 months
Other outcomes:
measure: Objective response rate(ORR)
timeFrame: Up to11 months
measure: Adverse reactions（AE） and Serious adverse reactions （SAE)
timeFrame: Through study completion, an average of 15 months
Locations:
city: Shenyang
country: China
facility: Shengjing Hospital of China Medical University
state: Liaoning
Study officials:
References:
Clinical trial NCT05387590: Health Care Provider Preventiomter Study
Official title: Health Care Providers Perceptions, Ratings and Motivation to Adopt/Utilize a Novel and State of the Art Physical Wellness Assessment Device (Preventiometer)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Wellness
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate health care providers' perceptions, ratings and motivation to adopt a novel and state of the art physical wellness assessment device, the Preventiometer.

Detailed description: The Preventiometer is a physical wellness tool that assesses multiple physical wellness measurements in a 60 +/- 15 minute period of time.

Eligibility criteria: Inclusion Criteria:

* Health care providers practicing at Mayo Clinic.
* Able to speak English and complete surveys.
* Able to read, understand and sign inform consent.

Exclusion Criteria:

* Unable to sign inform consent.
* Pregnant women. (As verbalized by participant).
* Unable to ambulate without assistance.
* Not currently involved in another formal program or research study involving wellness coaching.

Primary outcomes:
measure: Likert scale questionnaire on Preventiometer Wellness Assessment
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Brent Bauer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03614390: Mindfulness for Medical Students
Official title: Mindfulness for Medical Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mindfulness
Burnout, Professional
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2018-08-03
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Burnout is common among medical students. Previous studies had shown that mindfulness based interventions may improve burnout and quality of life in medical students. Mindfulness-based cognitive therapy (MBCT) is one of the most often used mindfulness based interventions.

Medical students in the Chinese University of Hong Kong are invited to a MBCT on voluntary basis. They will be asked to fill in questionnaire that measures burnout, depression/anxiety, quality of life, and mindfulness at beginning and end of the MBCT. The pre-group and post-group data will be compared and analysed


Eligibility criteria: Inclusion Criteria:

* Medical students studying in Chinese University of Hong Kong

Exclusion Criteria:

* The investigators did not set any exclusion criteria

Primary outcomes:
measure: Maslach Burnout Inventory (MBI)
timeFrame: 8 weeks (before and after MBCT; after 8 weekly sessions)
Secondary outcomes:
measure: 21-item Depression Anxiety Stress Scale (DASS-21)
timeFrame: 8 weeks (before and after MBCT; after 8 weekly sessions)
measure: the World Health Organization Quality of Life Assessment (WHOQOL-BREF)
timeFrame: 8 weeks (before and after MBCT; after 8 weekly sessions)
measure: Five Facet Mindfulness Questionnaire (FFMQ)
timeFrame: 8 weeks (before and after MBCT; after 8 weekly sessions)
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Lek Yuen Clinic
Study officials:
References:
Clinical trial NCT03415490: Self-adherent Wrap Techniques for Orbital Surgery
Official title: Folded and Classic Techniques of Self-adherent Wrap for Eyes After Orbital Tumour Extirpation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgery
Eye Diseases
Keywords: general anesthesia
self-adherent wrap
pressure
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2018-01-30
Enrollment: 128
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the interface pressure measurements of applying self-adherent wraps on eyes after orbital tumour extirpation.

Detailed description: The purpose of this study is to evaluate the interface pressure measurements of the folded and classic techniques of applying self-adherent wraps on eyes after orbital tumour extirpation.

Eligibility criteria: Inclusion Criteria:

* over 16 years old
* diagnosed as orbital disease or ocular tumor
* surgery under general anesthesia

Exclusion Criteria:

* any uncontrolled clinical problems

Primary outcomes:
measure: the pressure on the affected eye
timeFrame: 10 minutes after bandage application in awake individuals
Secondary outcomes:
measure: the pressure outside the affected eye
timeFrame: 10 minutes after bandage application in awake individuals
measure: discomfort scores
timeFrame: 1 minute after recording the pressures
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Huijing Ye Ye
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05643690: Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
Official title: Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay in Subjects Suspected of Having Bladder Cancer
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Bladder Cancer
Lead sponsor: AnchorDx Medical Co. Ltd. US
Sponsor class: INDUSTRY
Collaborators: name: AnchorDx Medical Co., Ltd.
name: Specialty Networks
First posted: 2022-12-09
Enrollment: 77
Sex: ALL
Minimum age (years): 55
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The clinical validation group is to assess the safety and effectiveness of the AnchorDx UriFind™ Bladder Cancer Assay in an intended use population to establish the expected performance in the product labeling. The study also aims to provide performance evidence of the AnchorDx UriFind™ Bladder Cancer Assay in adequate number of early-stage and low-grade cases.

Brief summary: The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.


Eligibility criteria: Inclusion Criteria:

Clinical Validation Group:

1. 55 years or older, gender is not limited
2. Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT)
3. Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis
4. Can provide at least of 75 ml of urine (prior to cystoscopy or surgery)

Exclusion Criteria:

1. History of urinary cancer
2. Neoadjuvant therapy

Primary outcomes:
measure: Sensitivity and Specificity of UriFind assay in detecting early stage Bladder Cancer
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Urology
state: Arkansas
city: Meridian
country: United States
facility: Idaho Urologic Institute
state: Idaho
Study officials:
affiliation: AnchorDx Medical Co., Ltd.
name: Jianbing Fan, Ph.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT03353090: Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
Official title: Incremental Diagnostic Utility of Systematic Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Metastases
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2017-11-27
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients

Brief summary: Bone scintigraphy is currently a reference test in the initial staging of cancer. Bone scintigraphy historically consists in a planar whole-body scintigraphy (WBS). SPECT/CT has been shown to dramatically reduce the proportion of inconclusive results and increase the specificity of bone scintigraphy. Therefore, in most of nuclear médicine centers, the usual protocol for staging of bone metastases consists in a whole-body planar acquisition followed, if needed, by a targeted SPECT/CT to characterize suspicious or equivocal uptakes seen on WBS. The aim of this study is to assess the incremental diagnostic utility of a systematic double-bed SPECT/CT acquisition for bone scintigraphy in initial staging of cancer patients compared with the conventional "WBS plus single-bed targeted SPECT/CT" strategy.

Detailed description: Images are interpreted by two nuclear medicine physicians in a 3-step procedure and by consensus. Firstly,only WBS planar images are considered. Secondly, a single-bed SPECT/CT chosen based on planar images is used if WBS demonstrated any equivocal or suspicious uptake.

Finally, WBS and double-bed SPECT/CT images are used for interpretation.

A per-lesion, a per-anatomical region and a per-patient analysis is performed. At each step, lesions, regions and diagnostic conclusions are classified using a 3-level scale, as negative for malignancy, equivocal or suspicious for metastasis

Eligibility criteria: Inclusion Criteria:

* Patients referred for bone scintigraphy for initial staging of biopsy proven malignancy.

Exclusion Criteria:

* monoclonal gammapathy
* patients under 18 years of age
* Technical issues not allowing a double-bed SPECT/CT acquisition
* double bed SPECT/CT acquisition not centered from the upper cervical spine to the proximal femora

Primary outcomes:
measure: Diagnostic impact of a systematic double SPECT/CT as compared to a oriented single-bed SPECT/CT bone scintigraphy for staging of malignancies with bone scintigraphy
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References:
Clinical trial NCT06874790: RCT for Latina Mental Health Using Web-Based Apps
Official title: Randomized Controlled Trial of a Choice-driven, Interactive, Storytelling Web-based App to Investigate Mental Health Treatment Initiation Among Symptomatic Latinas
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mental Health
Anxiety
Depression
Well-Being, Psychological
Keywords: Latina
Women
Therapy
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2025-03-13
Enrollment: 700
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Individual-level randomized controlled trial
Primary purpose: TREATMENT

Brief summary: This study compares a choice-driven, interactive, evidence-informed storytelling web-based app intervention with links to resources and treatment (Tx) recommendations (made by a character via her blog) and Tx locator, to a web-based app with links to publicly available informational internet videos, MH resources, and a treatment locator for at least moderately anxious/depressed untreated English and Spanish speaking Latinas to determine if a story-based, character-driven approach is more effective for catalyzing mental health treatment initiation.


Eligibility criteria: Inclusion Criteria:

* Latina (women who are from or have family ties to Latin America)
* Currently resides in LA or Orange County
* Age 18 and older
* Able to speak, read, and write in English or Spanish
* Score 10 or higher on GAD-7 and/or PHQ-8
* Access to the internet via smartphone, tablet, or computer
* Not currently receiving mental health therapy or pharmacotherapy
* Has not accessed mental health services during the previous 6 months

Exclusion Criteria:

* Not Latina or Hispanic
* Under age 18

Primary outcomes:
measure: Number of Participants Initiating Mental Health Treatment (MH Tx)
timeFrame: 9 months
Secondary outcomes:
measure: Psychological openness
timeFrame: 9 months
measure: Mental health help seeking attitude
timeFrame: 9 months
measure: Propensity to seek help
timeFrame: 9 months
measure: Indifference to Stigma
timeFrame: 9 months
measure: Stigma Concerns
timeFrame: 9 months
Other outcomes:
measure: Depression
timeFrame: 9 months
measure: Anxiety
timeFrame: 9 months
Locations:
Study officials:
affiliation: UCLA School of Nursing
name: MarySue V. Heilemann, PhD,RN,FAAN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05901103: The Efficacy of SPSIPB on Postoperative Pain and Analgesic Consumption in Patients Undergoing VATS
Official title: The Efficacy of Serratus Posterior Superior Intercostal Plane Block (SPSIPB) on Postoperative Pain and Total Analgesic Consumption in Patients Undergoing Video-assisted Thoracoscopic Surgery (VATS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post Operative Pain
Keywords: serratus posterior superior intercostal plane block
video assisted thoracoscopic surgery
postoperative pain
regional anesthesia
Lead sponsor: Cumhuriyet University
Sponsor class: OTHER
First posted: 2023-06-13
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study is to investigate the postoperative analgesic efficacy of SPSIPB and its effect on opioid consumption in patients undergoing video-assisted thoracoscopic surgery (VATS).

Detailed description: There were two randomized groups: Group S (SPSIPB) (n=12), Group C (no block) (n=12). All patients had standard general anesthesia. Group S had serratus posterior superior intercostal plane block (SPSIPB) with 0.25% bupivacaine (total volume of 30 ml) at the end of the surgery. Group Control had only tramadol for postoperative pain. Numerical rating scale (NRS) was used to assess postoperative pain on 1st, 6th, 12th and 24th hour after the surgery. Total tramadol consumption was calculated using patient-controlled analgesia (PCA) device.

Eligibility criteria: Inclusion Criteria:

* Adult patients older than 18 years of age who underwent video-assisted thoracoscopic surgery (VATS) under general anesthesia and were American Society of Anesthesiologists (ASA) I-II-III according to the ASA risk classification.

Exclusion Criteria:

* Patients who did not give consent,
* patients with coagulopathy,
* patients with signs of infection at the block application site,
* patients using anticoagulants,
* patients with local anesthetic drug allergies,
* patients undergoing open surgery,
* patients with unstable hemodynamics,
* patients who could not cooperate during postoperative pain assessment

Primary outcomes:
measure: Numerical rating scale (NRS) scores
timeFrame: Postoperative 24 hours
Secondary outcomes:
measure: Total tramadol consumption
timeFrame: Postoperative 24 hours
Other outcomes:
Locations:
city: Sivas
country: Turkey
facility: Sivas Cumhuriyet University
Study officials:
References:
citation: Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Korkmaz AO, Bozkurt NN, De Cassai A, Torres AJ, Elsharkawy H, Alici HA. Serratus Posterior Superior Intercostal Plane Block: A Technical Report on the Description of a Novel Periparavertebral Block for Thoracic Pain. Cureus. 2023 Feb 3;15(2):e34582. doi: 10.7759/cureus.34582. eCollection 2023 Feb.
Clinical trial NCT02853903: Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Malignant Solid Tumour
Keywords: solid tumor
NK immunotherapy
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
Collaborators: name: Shenzhen Hank Bioengineering Institute
First posted: 2016-08-03
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.

Detailed description: By enrolling patients with multiple kinds of solid tumor adapted to enrolled criteria, this study will document for the first time the short/long term efficacy of auto/allogenic NK cells.The outcome will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility criteria: Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
* Body tumor 1-6, the maximum tumor length \< 5 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Primary outcomes:
measure: Relief degree of tumors
timeFrame: 3 months
Secondary outcomes:
measure: Progress free survival（PFS）
timeFrame: 1 year
measure: Overall survival（OS）
timeFrame: 3 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Fuda cancer institute of Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital, Guangzhou
name: Jibing Chen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: